产品说明书

Trilostane

Print
Chemical Structure| 13647-35-3 同义名 : 曲洛斯坦 ;Win 24540;Desopan;Modrenal.;Modrastane. Desopan;D-01180;DB01108;Vetoryl;Modrefen
CAS号 : 13647-35-3
货号 : A378777
分子式 : C20H27NO3
纯度 : 99+%
分子量 : 329.433
MDL号 : MFCD00199295
存储条件：

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 55 mg/mL(166.95 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：

IP 2% DMSO+2% Tween80+40% PEG300+water 2 mg/mL clear

PO 0.5% CMC-Na 42 mg/mL suspension

生物活性
靶点

  • Dehydrogenase
描述 Trilostane is a recognized treatment for canine pituitary-dependent hyperadrenocorticism (PDH); The median survival time for animals treated with trilostane was 353 days (95% confidence interval [CI] 95-528 days)[3]. During trilostane therapy, urinary catecholamines and their metabolites did not decrease significantly. However, dogs with low post-ACTH cortisol concentrations during trilostane therapy had less increased epinephrine, norepinephrine and normetanephrine, creatinine ratios compared to healthy dogs[4]. In a substantial number of dogs treated with trilostane, the two prepill cortisol concentrations differed. Part of this difference might be ascribable to stressful events during test performance[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01615211 Medical Abortion, Complete or ... 展开 >>Unspecified, Without Complication 收起 << Phase 2 Terminated(No access to study ... 展开 >>drug Trilostan. Company closed down) 收起 << - Sweden ... 展开 >> Karolinska University Hospital Stockholm, Sweden, 17177 收起 <<
NCT00181597 Prostate Cancer ... 展开 >> Prostate Adenocarcinoma 收起 << Phase 2 Completed - United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.04mL

0.61mL

0.30mL

15.18mL

3.04mL

1.52mL

30.36mL

6.07mL

3.04mL
参考文献

[1]Feldman EC, Kass PH. Trilostane dose versus body weight in the treatment of naturally occurring pituitary-dependent hyperadrenocorticism in dogs. J Vet Intern Med. 2012 Jul-Aug;26(4):1078-80.

[2]Helm JR, McLauchlan G, et al. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane. J Vet Intern Med. 2011 Mar-Apr;25(2):251-60.

[3]Helm JR, McLauchlan G, Boden LA, Frowde PE, Collings AJ, Tebb AJ, Elwood CM, Herrtage ME, Parkin TD, Ramsey IK. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane. J Vet Intern Med. 2011 Mar-Apr;25(2):251-60

[4]Sieber-Ruckstuhl N, Salesov E, Quante S, Riond B, Rentsch K, Hofmann-Lehmann R, Reusch C, Boretti F. Effects of Trilostane on urinary Catecholamines and their metabolites in dogs with Hypercortisolism. BMC Vet Res. 2017 Sep 4;13(1):279

[5]Boretti F, Musella C, Burkhardt W, Kuemmerle-Fraune C, Riond B, Reusch C, Sieber-Ruckstuhl N. Comparison of two prepill cortisol concentrations in dogs with hypercortisolism treated with trilostane. BMC Vet Res. 2018 Dec 27;14(1):417